MCID: ANL011
MIFTS: 36

Anal Canal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Anal Canal Carcinoma

MalaCards integrated aliases for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 53 12 13 41 14
Carcinoma of Anal Canal 12 69
Anal Canal and Perianal Gland Carcinoma 12
Cancer of the Anal Canal 36

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
anal canal carcinoma:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 105580
Disease Ontology 12 DOID:6126
MeSH 41 C563020
NCIt 46 C7489
SNOMED-CT 64 285310000
MedGen 39 C0563211
KEGG 36 H00044
ICD10 32 C21.1
SNOMED-CT via HPO 65 263681008
UMLS 69 C0563211

Summaries for Anal Canal Carcinoma

Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

MalaCards based summary : Anal Canal Carcinoma, also known as carcinoma of anal canal, is related to anal carcinoma in situ and small cell carcinoma, and has symptoms including anal canal squamous carcinoma An important gene associated with Anal Canal Carcinoma is ANC (Anal Canal Carcinoma), and among its related pathways/superpathways are Viral carcinogenesis and Pathways in cancer. The drugs Capecitabine and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include liver, prostate and endothelial, and related phenotype is neoplasm.

Description from OMIM: 105580

Related Diseases for Anal Canal Carcinoma

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to Anal Canal Carcinoma

Symptoms & Phenotypes for Anal Canal Carcinoma

Symptoms via clinical synopsis from OMIM:

53
Oncology:
anal canal squamous carcinoma


Clinical features from OMIM:

105580

Human phenotypes related to Anal Canal Carcinoma:

31
# Description HPO Frequency HPO Source Accession
1 anal canal squamous carcinoma 31 HP:0006763

MGI Mouse Phenotypes related to Anal Canal Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDKN2A GLI1 NME1 NQO1

Drugs & Therapeutics for Anal Canal Carcinoma

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
2
Fluorouracil Approved Phase 2 51-21-8 3385
3
Daratumumab Approved Phase 1, Phase 2 945721-28-8
4
nivolumab Approved Phase 1, Phase 2 946414-94-4
5
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
6
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
7
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
8
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
9 Alkylating Agents Phase 2
10 Anti-Bacterial Agents Phase 2
11 Antibiotics, Antitubercular Phase 2
12 Antimetabolites Phase 2
13 Antimetabolites, Antineoplastic Phase 2
14 Immunosuppressive Agents Phase 2
15 Mitomycins Phase 2
16 Nucleic Acid Synthesis Inhibitors Phase 2
17 Antibodies Phase 1, Phase 2
18 Antibodies, Monoclonal Phase 1, Phase 2
19 Immunoglobulins Phase 1, Phase 2
20 Liver Extracts Phase 2
21 Antimitotic Agents Phase 2
22 taxane Phase 2
23 Albumin-Bound Paclitaxel Phase 2
24 Antineoplastic Agents, Phytogenic Phase 2

Interventional clinical trials:

(show all 17)

# Name Status NCT ID Phase Drugs
1 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
2 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
3 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
4 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
5 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
6 Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Active, not recruiting NCT02314169 Phase 2
7 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
8 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Active, not recruiting NCT00754078 Phase 2
9 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
10 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Not yet recruiting NCT03403465 Phase 2
11 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Not yet recruiting NCT03233711 Phase 2
12 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2 Nimotuzumab
13 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
14 Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer Completed NCT00325871
15 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779 DCF regimen
16 Individual Following in Anal Cancer With PET/CT Recruiting NCT02697084
17 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Active, not recruiting NCT01325961

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Genetic Tests for Anal Canal Carcinoma

Anatomical Context for Anal Canal Carcinoma

MalaCards organs/tissues related to Anal Canal Carcinoma:

38
Liver, Prostate, Endothelial, Skin

Publications for Anal Canal Carcinoma

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 67)
# Title Authors Year
1
Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. ( 27976366 )
2016
2
Anal Canal Carcinoma in a Child With Disorders of Sex Development. ( 27037640 )
2016
3
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. ( 25903798 )
2015
4
Shifting paradigm in the management of anal canal carcinoma. ( 25432583 )
2015
5
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? ( 25976929 )
2015
6
Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243421 )
2014
7
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. ( 24472223 )
2014
8
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243447 )
2014
9
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 23674135 )
2013
10
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. ( 24674573 )
2013
11
Changing patterns of anal canal carcinoma in the United States. ( 23509304 )
2013
12
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. ( 22529257 )
2012
13
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. ( 21395883 )
2012
14
Endobronchial metastases of anal canal carcinoma. ( 22055765 )
2012
15
Chemotherapy in the treatment of anal canal carcinoma. ( 22658644 )
2012
16
Anal canal carcinoma treatment results: the experience of a single institution. ( 21403412 )
2011
17
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. ( 21775274 )
2011
18
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. ( 22331724 )
2011
19
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. ( 21772841 )
2011
20
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. ( 20472349 )
2011
21
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( 20492729 )
2010
22
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. ( 19399614 )
2010
23
Post burn Marjolin's ulcer in the natal cleft mimicking anal canal carcinoma: a rare site. ( 21160444 )
2010
24
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. ( 19695047 )
2009
25
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( 18490648 )
2008
26
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. ( 18505075 )
2008
27
Chemotherapy and radiotherapy for anal canal carcinoma. ( 18812528 )
2008
28
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). ( 18191265 )
2008
29
The aspects of angiogenesis in anal canal carcinomas compared with that in colorectal carcinomas. ( 18060184 )
2007
30
External beam radiotherapy plus brachytherapy boost in treatment of anal canal carcinoma. ( 17988027 )
2007
31
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. ( 18005443 )
2007
32
Anal canal carcinoma with Pagetoid spread: report of a case. ( 16794808 )
2006
33
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. ( 16631268 )
2006
34
Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. ( 15890590 )
2005
35
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. ( 15752894 )
2005
36
Epidermal growth factor receptor expression in anal canal carcinoma. ( 15923158 )
2005
37
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. ( 12788191 )
2003
38
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. ( 11395235 )
2001
39
Analysis of a follow-up program for anal canal carcinoma. ( 11484975 )
2001
40
Prognostic impact of CD31 antigen expression in anal canal carcinoma. ( 11677963 )
2001
41
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life. ( 11398611 )
2001
42
An unusual late radiotherapy-related complication requiring surgery in anal canal carcinoma. ( 10914830 )
2000
43
nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis? ( 10914829 )
2000
44
Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. ( 11277325 )
2000
45
Patterns of recurrence in anal canal carcinoma. ( 10982516 )
2000
46
Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. ( 10435803 )
1999
47
Human papillomavirus infection and p53 nuclear overexpression in anal canal carcinoma. ( 10374676 )
1999
48
Correlation between nm23-H1 overexpression and clinicopathological variables in human anal canal carcinoma. ( 10523705 )
1999
49
Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? ( 9559628 )
1998
50
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. ( 9572617 )
1998

Variations for Anal Canal Carcinoma

Expression for Anal Canal Carcinoma

Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for Anal Canal Carcinoma

Pathways related to Anal Canal Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

Pathways related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.52 CDKN2A GLI1 NQO1

GO Terms for Anal Canal Carcinoma

Sources for Anal Canal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....